✚ HEALTH & MEDICINE 50 YEARS HORIZON RESOLVES 2 NOV 2076 · in 50y

The FDA approves a universal cure or broadly curative therapy for all major forms of cancer before 2050.

Cancer encompasses hundreds of distinct diseases, making a single universal cure biologically complex. Resolution requires regulatory approval of a treatment that reliably cures the majority of cancer types.

Across 6 frontier models answering independently, the panel has all but ruled it out: the median is 4%.

They broadly agree, 15 points between GPT at 18% and DeepSeek at 3%.

Nothing is settled until 2 Nov 2076, when the outcome is checked against sources and every number above gets a permanent score.

MODEL BY MODEL

What each one said

  • GPTOpenAI

    This hinges on whether shared cancer vulnerabilities can yield durable cures across highly diverse tumors, not just broad response rates.

    • FDA would need pivotal trials showing reliable cures across most major cancers, a far higher bar than approvals for tumor-agnostic subsets.
    • Since 2017, tumor-agnostic approvals have covered biomarker-defined minorities; no therapy has cured most common solid tumors.
    • I would raise this sharply if multi-cancer trials showed long-term, treatment-free remission across several common solid-tumor classes.
    openai/gpt-5.6-terra · asked 15 Nov 2026
    18%
  • GrokxAI

    One FDA-approved agent must show durable cures across most major solid and hematologic cancers.

    • Pharma and FDA need multi-indication Phase 3 data by ~2048 showing majority-type cure rates, not incremental OS gains.
    • No historical analog exists; even checkpoint inhibitors and CAR-T remain subtype-limited after 15+ years.
    • A pan-cancer shared vulnerability proven in humans by 2031 would raise this sharply; none is in late trials now.
    x-ai/grok-4.6 · asked 15 Nov 2026
    8%
  • GeminiGoogle

    Tumor heterogeneity and divergent oncogenic drivers make a single pan-cancer curative mechanism biologically implausible by 2050.

    • FDA pan-tumor approvals like pembrolizumab target specific biomarkers, but no single pathway spans all major solid and liquid malignancies.
    • Drug discovery cycles take 10 to 15 years, meaning any candidate entering trials after 2035 would miss the 2050 approval window.
    • An AI-engineered multi-antigen programmable nanoparticle clearing Phase 3 trials across five distinct cancer types would flip this to 25%.
    google/gemini-3.8-flash · asked 15 Nov 2026
    4%
  • ClaudeAnthropic

    Cancer's molecular diversity makes a single curative therapy for all major types biologically implausible even by 2050.

    • Oncology research trends toward tumor-specific and personalized therapies, not convergence on one universal mechanism.
    • Decades of immunotherapy, CRISPR, and mRNA advances have improved survival but none approach a 'cure all cancers' profile.
    • A surprise unifying biological mechanism (e.g. universal targeting of a shared tumor vulnerability) reaching FDA approval would be the game-changer.
    anthropic/claude-sonnet-5 · asked 15 Nov 2026
    4%
  • DeepSeekDeepSeek

    A single therapy curing all major cancers is biologically implausible and no such agent is in late-stage trials.

    • FDA approval requires a single therapy to clear Phase III trials across many histologies, and no such pan-cancer agent is in late-stage trials today.
    • The 24-year window is long, but cancer's 200+ subtypes and heterogeneous resistance mechanisms make a universal cure biologically implausible on this timeline.
    • Targeted and immunotherapies are advancing, but they cure subsets, not all major forms; a universal cure would require a paradigm shift not yet visible.
    deepseek/deepseek-v4.1-flash · asked 15 Nov 2026
    3%
  • QwenAlibaba

    Cancer's biological heterogeneity makes a single curative mechanism across all major types implausible within 24 years.

    • No therapy in history has cured more than a few cancer types; checkpoint inhibitors and CAR-T each address narrow subsets, not a universal mechanism.
    • Even if a platform like engineered T-cells or mRNA vaccines showed pan-cancer promise by ~2035, FDA approval for 'cures majority of types' would require separate pivotal…
    • A shift would require discovering a truly universal vulnerability (e.g., a shared metabolic dependency) that current oncology has not identified after 50+ years of…
    qwen/qwen3.8-max-0902 · asked 15 Nov 2026
    3%

6 of 6 models answered · 15 points between the highest and lowest. None was shown the market price.

WHAT DO YOU THINK?
loading…

Question sourced from a news sweep on 15 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.